Clinical trials in Hoofddorp – page 23

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hoofddorp at a glance

1 940

clinical trials

Research sites1

Quick filters

1 940 trials in Hoofddorp

Open in trial search

Non-small cell lung cancer+1

Recruiting

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Transplant rejection+1

Recruiting

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Beta haemolytic streptococcal infection

Recruiting

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

The Netherlands

Participants:18–64 years
Substances:Dapagliflozin
Sponsor:University Of Cologne

Contact Research Centre

Facioscapulohumeral muscular dystrophy

Recruiting

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Avidity Biosciences Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

Registered drugNo placebo

A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:BAY 3713372
Sponsor:Bayer AG

Contact Research Centre

Phenylketonuria

Recruiting

A Study of Repinatrabit Compared to Placebo for Treatment of Patients with Phenylketonuria

Investigational

A Study of Repinatrabit Compared to Placebo for Treatment of Patients with Phenylketonuria

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Repinatrabit
Sponsor:Otsuka Pharmaceutical Development And Commercialization Inc.

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Erdafitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Renal cell carcinoma

Recruiting

Testing Cabozantinib Dose Skipping Schedule Compared to Dose Reduction in Patients with Kidney Cancer Taking Cabozantinib Treatment

Registered drugNo placebo

Testing Cabozantinib Dose Skipping Schedule Compared to Dose Reduction in Patients with Kidney Cancer Taking Cabozantinib Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

Advanced/Metastatic Breast Cancer Treatments
Urothelial Cancer Therapies
Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

B-Cell Lymphoma Treatments
Myelofibrosis Therapies
Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

Weight Management Interventions
Surgical Techniques
Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the Netherlands All countries